TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01440166
Drug: Drug
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose oral administration of CAT1004 or placebo-6 to 8 subjects will be treated with CAT-1004 per cohort.
Study: NCT02785159
Drug: IDP-118 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotion
Study: NCT02785159
Drug: IDP-118 Vehicle Lotion
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotion
Study: NCT02785159
Drug: IDP-118 Vehicle Cream
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream
Study: NCT01640951
Drug: AIN457 150 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: (1 injection per dose) and placebo to Secukinumab 150 mg
Study: NCT01640951
Drug: AIN457 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg (2 injections per dose)
Study: NCT01640951
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02298166
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy:~Placebo to be given as p.o. TID starting d 7+, given continuously thereafter until 48 hours prior to the next chemotherapy.~Consolidation therapy:~Placebo will start on day 4, thereafter with continuous dosing until 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy with placebo is intended in all patients after allogeneic HCT or intermediate-dose cytarabine consolidation therapy. Maintenance therapy will be given for 364 days (equivalent to 13 cycles à 28 days) after recovery from allogeneic HCT or IDAC.~Maintenance with placebo will be given at the same dose tolerated during induction therapy.
Study: NCT02551237
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral capecitabine 800 mg/m2 twice daily from the first day of radiotherapy and given 5 days per week during radiotherapy.
Study: NCT01404585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, twice daily, 12 weeks
Study: NCT00494949
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200, 400, 600, 750, or 1000 mL of Ringer's lactate solution
Study: NCT04473703
Drug: renin-angiotensin system inhibitors or angiotensin-receptor-neprilysin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with odd random number will treat with RASI（renin-angiotensin system inhibitors）, and those with even random number will treat with ARNI（angiotensin-receptor-neprilysin inhibitor）
Study: NCT03800212
Drug: treatment for ampullary adenocarcinoma
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: all patients treated for ampullary adenocarcinoma (particularly survival without recurrence and prognostic indicators for excised tumours and the duration of disease control for tumours treated with palliative chemotherapy).
Study: NCT02224105
Drug: Prednisolone low
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02224105
Drug: Prednisolone high
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02224105
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02867059
Drug: (+)-SJ000557733
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+)-SJ000557733 (SJ733), in short SJ733, will be the second PfATP4 inhibitor to enter clinical development after KAE609 (Novartis) which is currently in Phase 2 stage. KAE609 (cipargamin; previously known as NITD609) is a spirotetrahydro-β-carbolines (spiroindolone). KAE609 inhibits QP15C20_SJ733_Challenge Protocol_v2.0_26July2016 Page 28 of 110 PfATP4, which results in a disruption of parasite sodium homeostasis. Compared to KAE609, SJ733 has the potential to be a very fast acting, antimalarial drug for human therapeutic application and may have a different safety profile in human participants. Finally, SJ733 blocks parasite transmission in vivo at potencies close to those where it is efficacious in blood stages, indicating its potential for transmission blockade in humans.
Study: NCT03840902
Drug: M7824
Normalized name: M7824
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received intravenous infusion of 1200 milligram (mg) M7824 over 1 hour every 2 weeks (q2w) during cCRT and up to 1 year after cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
Study: NCT03840902
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received intravenous infusion of placebo matched to M7824 over 1 hour q2w during cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
Study: NCT01379482
Drug: Multimodal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months (range 2-4.5) with neoadjuvant systemic chemotherapy. Four weeks after receiving the last course of chemotherapy, patients will undergo laparotomy with the objective of performing cytoreduction + hyperthermic intraperitoneal chemotherapy.~Early peritoneal chemotherapy though intrabdominal drains for the first five postoperative days.~Neo-adjuvant chemotherapy:~Irinotecan+Nordic FLv (6 pat.) EOX (6 pat.) FLOX (3 pat.) Docetaxel+Irinotecan+5-FU+LV (1 pat.) FOLFIRI (1 pat.) ECF (1 pat.)~Hyperthermic intraoperative chemotherapy:~Cisplatin+doxorubicin (5 pat.). Oxaliplatin +concomitant i.v. 5-FU+ i.v. LV (3 pat.)~Early postoperative chemotherapy:~5-FU + i.v. LV (5 pat.) Paclitaxel (1 pat.)
Study: NCT00003593
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00003593
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IT
Study: NCT02029235
Drug: Acetaminophen/Ibuprofen
Normalized name: ACETAMINOPHEN/IBUPROFEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperatively, subjects will be given acetaminophen 500 mg / ibuprofen 400mg every 4 hours, as needed, for one week or until essentially pain-free
Study: NCT02029235
Drug: Acetaminophen/Hydrocodone
Normalized name: ACETAMINOPHEN/HYDROCODONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperatively, subjects will be given acetaminophen 325 mg / hydrocodone 5 mg every 4 hours, as needed, for one week or until essentially pain-free
Study: NCT01102673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match PF-04991532 will be provided
Study: NCT01855516
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01367236
Drug: standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: * atazanavir 300 mg daily~* ritonavir 100 mg daily~* tenofovir 245 mg daily\*~* emtricitabine 200 mg daily\*
Study: NCT01367236
Drug: novel treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: * darunavir 800 mg daily~* ritonavir 100 mg daily~* lamivudine 300 mg daily\*\* and abacavir 600mgs daily\*\*~* maraviroc 150 mg once daily
Study: NCT02757469
Drug: Drospirenone and ethinyl estradiol combination (Yasmin)
Normalized name: drospirenone / ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Female oral combined contraceptive containing 30 mcg (0.030 mg) Ethinyl Estradiol and 3 mg drospirenone (Androstenes)
Study: NCT00679770
Drug: AN2690, 7.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application for 90 days and 3 x weekly for 90 days
Study: NCT00679770
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application for 90 days and 3x weekly for 90 days
Study: NCT00736463
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One arm of randomized crossover
Study: NCT03936023
Drug: Sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2nd generation sulfonylurea dispensing claim is used as the reference
Study: NCT01595282
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For subjects weighing over 50 kg, ketorolac 60 mg in 2cc administered via intramuscular injection 30-60 minutes before suction curettage procedure. For subjects weighing 50 kg or less, ketorolac 30 mg in 1 cc administered via intramuscular injection 30-60 minutes before suction curettage procedure
Study: NCT01595282
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For subjects weighing over 50 kg, ibuprofen 800 mg tablet administered orally 60-90 minutes before suction curettage procedure. For subjects weighing 50 kg or less, ibuprofen 600 mg tablet administered orally 60-90 minutes before suction curettage procedure.
Study: NCT02107261
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT00359658
Drug: prednisolon
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisolon withdrawal: reduction of maintenance dosage, 0,5 mg of the daily dose every week till withdrawal
Study: NCT00359658
Drug: Mycophenolatmofetile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycophenolatmofetile administration: start doses 250 mg, increase of the daily dose about 250 mg every week till reaching 2 g/daily
Study: NCT01222442
Drug: AZD3199
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, oral inhalation
Study: NCT02431273
Drug: TDF IVR
Normalized name: Ivra
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00163046
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo 30 minutes prior to bedtime for 28 days
Study: NCT00056966
Drug: CAMPATH-1H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day -8 through Day -6 Dosed per Institutional SOP
Study: NCT02213146
Drug: Huminsulin® Normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 0.2 U/kg body weight injected subcutaneously
Study: NCT02071043
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1\~14 every 3
Study: NCT00692185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of placebo once each evening for 8 weeks.
Study: NCT01701401
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDV/SOF 90/400 mg FDC tablet administered orally once daily
Study: NCT02134262
Drug: Cyclophosphamide or Bendamustine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide \[1.5 g/m\^2 x 1 day Intravenous (IV)\] or Bendamustine \[120 mg/m\^2 x 2 days Intravenous (IV)\] is administered as Pre-treatment medication of CD19-CAR-T.
Study: NCT00311714
Drug: CS-8958 formulated as dry powder
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03959384
Drug: Curosurf 80Mg/Ml Intratracheal Suspension
Normalized name: Curosurf 80mg/ml Intratracheal Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: CUROSURF is a natural surfactant obtained from swine lungs containing almost exclusively phospholipids, in particular phosphatidylcholine (about 70% of the total phospholipid content) and about 1% of low molecular weight hydrophobic proteins, specific for surfactant, SP-B and SP -C. CUROSURF will be administered via endotracheopulmunary.
Study: NCT00585156
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twelve hours prior to their first total knee surgery, patients will need to take an oral dose of Celebrex, 1 pill of 200mg. Following the patient's first total knee surgery, they will continue taking oral doses of Celebrex, 1 pill of 200 mg every twenty-four hours (200mg/day) for a two-week period.
Study: NCT00563134
Drug: GR270774
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01219790
Drug: Acide zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The administration of zoledronic acid as defined under the Authorisation on the Market.
Study: NCT01371994
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00061906
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment will be administered on an outpatient basis. Oral celecoxib will be given at the dose of 400 mg BID for total of 12 months. Patients will be advised to take this medication with food to improve absorption.
Study: NCT03057600
Drug: CB-839
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB-839 administered as oral tablets twice daily (BID)
Study: NCT00447837
Drug: SPRC-AB01
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg/3 mL BID, 180 mg/3 mL bid, placebo
Study: NCT00895596
Drug: LB80380
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total treatment period: 12 weeks, followed by 24 weeks of treatment with adefovir dipivoxil 10mg
Study: NCT01084525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm will be conducted in parallel with each OTO-104 dose cohort.
Study: NCT01270282
Drug: AM-101 0.81 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01270282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04011930
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80,000 IU(2 capsules)/week for 13 weeks and then according to the serum calcium and serum D level 40,000 IU/2 to 3 weeks for next 13 weeks
Study: NCT00989742
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg od
Study: NCT00989742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg od
Study: NCT03261466
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03806309
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV); folinic acid 400 mg/m\^2, irinotecan 180 mg/m\^2, 5-FU bolus 400 mg/m\^2 and continuous infusion 2,400 mg/m\^2
Study: NCT03806309
Drug: OSE2101
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection on days 1 and 15, every 4 weeks for 6 doses then every 8 weeks until month 12 and then every 12 weeks for a maximum treatment duration of 24 months
Study: NCT00395759
Drug: Optiva artificial tear by Allergan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01105975
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered daily by mouth for 12 weeks
Study: NCT01105975
Drug: Placebo for LY2484595
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered daily by mouth for 12 weeks
Study: NCT01105975
Drug: Placebo for Statins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered daily by mouth for 12 weeks
Study: NCT01372085
Drug: LY2584702 Reference Formulation
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01372085
Drug: LY2584702 Test Formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01372085
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00732849
Drug: Reconvan, Dipeptiven, Omegaven
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reconvan (1ml=1 kcal), 30 kcal/kg b.w. Omegaven 1 ml/ kg b.w. Dipeptiven 1 ml/ kg b.w.
Study: NCT04898569
Drug: Normal Saline Flush
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00403494
Drug: Sapropterin Dihydrochloride
Normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects receive 400 mg oral sapropterin dihydrochloride twice daily for 24 weeks.
Study: NCT02347332
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01215747
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally 1 to 3 capsules (placebo) twice daily and adjusted as per the Creatine Clearance (CrCl) level increases or decreases:
Study: NCT03912909
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomly assigned to receive either Empagliflozin 10mg/daily or Placebo and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 4-week treatment phases will be separated by a 4-week wash out (drug-free) period. The study will consist of a total of 5 visits conducted over approximately 18 weeks; one screening visit, one baseline visit, 1 short visit at the start of the second treatment phase and 2 comprehensive testing visits, each at the end of the two treatment phases
Study: NCT02432066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo pills, compounded by the UF investigational pharmacy
Study: NCT01894399
Drug: HM61713
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1 : 100mg single dose in Korean Cohort 2 : 200mg single dose in Korean Cohort 3 : 300mg single dose in Korean Cohort 4 : 200mg single dose in Japanese Cohort 5 : 300mg single dose in Japanese Cohort 6 : 200mg single dose in Caucasian Cohort 7 : 300mg single dose in Caucasian
Study: NCT01562834
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months. After treatment in the randomised trial period, placebo will be discontinued.
Study: NCT00885313
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02118311
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 from transplant
Study: NCT02325349
Drug: radiopharmaceutical (Flotegatide (18F) or RGD (68Ga)
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET/CT after intravenous administration of 2-4MBq/kg of body weight of Flotegatide (18F) or RGD (68Ga) performed prior and after 2 cycles of chemotherapy including an agent with antiangiogenic effect (two examinations in each patient)
Study: NCT00802126
Drug: Combination therapy IVB + rf-PDT
Normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: low-fluence photodynamic therapy combined with intravitreal bevacizumab
Study: NCT05208034
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two-doses of intramuscular methotrexate as 50mg/m2.. One at at day-zero and 2nd at day 7.
Study: NCT02079649
Drug: AL-53817 Ophthalmic Solution, 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02079649
Drug: AL-78843 Ophthalmic Solution, 0.03%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01408394
Drug: 90 mg controlled release form
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is the 90 mg controlled release form
Study: NCT01408394
Drug: 180 mg controlled release form
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is the 180 mg controlled release capsule
Study: NCT02974322
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01500200
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo tablets, given daily
Study: NCT01767467
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.
Study: NCT01260896
Drug: Effexor® XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg Extended-Release Capsule
Study: NCT02629224
Drug: ASP8825
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02275611
Drug: Intranasal Placebo Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Placebo Spray
Study: NCT05088798
Drug: 18F-Fluoro Dopa PET/MRI Imaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: The purpose of this research study is to provide access to an imaging study of the pancreas that uses 6-\[18F\]-Fluoro-L-3,4,-dihydroxyphenylalanine (18F-DOPA)positron emission tomography (PET) and assess the accuracy of this 18F-DOPA-PET/MRI test on distinguishing what part of the pancreas is affected in patients with Hyperinsulinism.
Study: NCT00477893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sc. inj. placebo every other week, week 0, 2, 4, 6, 8, and 10.
Study: NCT00008242
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02513043
Drug: medical abortion
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: medical abortion
Study: NCT00556478
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is a metered dose aerosol spray that is identical in appearance to the active treatment and contains the same propellant (norflurane) but has no lidocaine or prilocaine.~Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.~During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing.~During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period.
Study: NCT00257881
Drug: CMD-193
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02397096
Drug: Baseline regimen of a non-nucleoside reverse transcriptase inhibitor
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline regimen of antiretroviral therapy with a NNRTI (efavirenz, nevirapine, or rilpivirine) administered according to the product circular
Study: NCT02397096
Drug: Baseline regimen of two nucleoside reverse transcriptase inhibitors
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline regimen of antiretroviral therapy with two NRTIs administered according to the product circular